Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.
Issues related to opioids
Medicaid rebate CPI
drug pricing issues
Duration: January 4, 2010
to
February 1, 2018
General Issues: Health Issues , Medicare/Medicaid , Labor Issues/Antitrust/Workplace , Copyright/Patent/Trademark , Budget/Appropriations
Spending: about $1,654,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2010: U.S. Senate, House of Representatives, White House Office, Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Ginger Loper Special Assistant to the President 2003-2005
Special Assistant to the President for Legislative Affairs (2002-2005)
special assistant to the President 2002-2005
Special Assistant to the President 2002-2005
special Assistant to the President (2002-2005)
Special Assistant to the President (2002-2005)
Spec Asst to the President for Legislative Affairs
Special Assistant to the President - WH Leg Affair
Special Assistant the President - WH Leg Affairs
Special Asst to the President - WH Leg Affairs
Special Assistant to the President - WH Leg Affiar
Special Assistant to the President - WH Leg Affairs
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2018
Loper Consulting LLC terminated an engagement in which they represented Teva Pharmaceuticals USA on March 21, 2018.
Original Filing: 300941736.xml
4th Quarter, 2017
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Feb. 8, 2018.
Original Filing: 300939976.xml
Lobbying Issues
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.
Issues related to opioids
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate CPI
drug pricing issues
Agencies Lobbied
U.S. Senate
3rd Quarter, 2017
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Oct. 27, 2017.
Original Filing: 300917825.xml
Lobbying Issues
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.
FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement.
Issues related to H.R. 1628, the American Health Care Act.
Better Care Reconciliation Act (BCRA)
Issues related to opioids
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate CPI
drug pricing issues
Agencies Lobbied
U.S. Senate
2nd Quarter, 2017
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Aug. 8, 2017.
Original Filing: 300899297.xml
Lobbying Issues
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.
FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement.
Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate CPI/ pricing
Agencies Lobbied
U.S. Senate
1st Quarter, 2017
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on May 8, 2017.
Original Filing: 300879850.xml
Lobbying Issues
Issues related to affordability and pricing of pharmaceuticals including S.771 Improving Access to Affordable Prescription Drugs Act.
FDA user fee agreements, including the Prescription Drug User Fee Agreement and the Generic Drug User Fee Agreement.
Issues related to H.R. 1628, the American Health Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate CPI/ pricing
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848534.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
S. 484 and HR 1353 PATIENTS Act of 2015
21st Century Cures/innovation
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate on generic drugs where costs increase by more than the CPI
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on May 8, 2017.
Original Filing: 300879853.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
S. 484 and HR 1353 PATIENTS Act of 2015
Senate HELP working group on Innovation for Healthier Americans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate on generic drugs where costs increase by more than the CPI
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Aug. 3, 2016.
Original Filing: 300823213.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
S. 484 and HR 1353 PATIENTS Act of 2015
Senate HELP working group on Innovation for Healthier Americans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate on generic drugs where costs increase by more than the CPI
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on May 2, 2016.
Original Filing: 300804636.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
S. 484 and HR 1353 PATIENTS Act of 2015
Senate HELP working group on Innovation for Healthier Americans
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicaid rebate on generic drugs where costs increase by more than the CPI
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Feb. 3, 2016.
Original Filing: 300786018.xml
Lobbying Issues
H.R.2029 - Consolidated Appropriations Act, 2016
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
S. 484 and HR 1353 PATIENTS Act of 2015
Senate HELP working group on Innovation for Healthier Americans
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Oct. 20, 2015.
Original Filing: 300760590.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
S. 484 and HR 1353 PATIENTS Act of 2015
Senate HELP working group on Innovation for Healthier Americans
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on July 16, 2015.
Original Filing: 300735918.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
HR 6 21st Century Cures
Senate HELP working group on Innovation for Healthier Americans
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on April 20, 2015.
Original Filing: 300727088.xml
Lobbying Issues
S 2948 Medicaid Generic Drug Price Fainess Act
H.R.1353 PATIENT Act of 2015
Lobbied on issues related to abuse deterrent formulations of drugs and prescription drug abuse
FDA proposed rule on generic drug labels
Agencies Lobbied
U.S. Senate
4th Quarter, 2014
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals USA , earning $50,000. The report was filed on Jan. 21, 2015.
Original Filing: 300708489.xml
Lobbying Issues
Lobbied on issues related to abuse deterrent formulation of drugs &prescription drug abuse. FDA proposed rule on generic drug labels
S. 2948 Medicaid Generic Drug Price Fairness Act
Lobbied on a policy related to incentives for New Therapeutic Entities
Agencies Lobbied
U.S. Senate
3rd Quarter, 2014
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $50,000. The report was filed on Nov. 3, 2014.
Original Filing: 300690673.xml
Lobbying Issues
Lobbied on issues related to abuse-detterant formulation of drugs, prescription drug abuse, FDA proposed rule on generic drug labels, generic drug prices
Agencies Lobbied
U.S. Senate
2nd Quarter, 2014
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $50,000. The report was filed on July 23, 2014.
Original Filing: 300670327.xml
Lobbying Issues
lobbied on issues related to non-biologic complex drugs, abuse-deterrent formulation of drugs, prescription drug abuse, FDA proposed rule on generic drug labeling.
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $50,000. The report was filed on April 21, 2014.
Original Filing: 300646421.xml
Lobbying Issues
lobbied on issues related to non-biologic complex drugs (NBCD), abuse-deterrent formulation of drugs, prescription drug abuse, FDA proposed rule on generic drug labeling.
monitored SGR legislation as it related to payfors in the pharmaceutical drug space.
4th Quarter, 2013
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $50,000. The report was filed on Jan. 20, 2014.
Original Filing: 300621783.xml
Lobbying Issues
S.RES.97 : A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
S. 959, Pharmaceutical Compounding Quality and Accountability Act
S. 957, Drug Supply Chain Security Act
H.R.3204 Drug Quality and Security Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2013
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on Oct. 24, 2013.
Original Filing: 300608339.xml
Lobbying Issues
S. 959, Pharmaceutical Compounding Quality and Accountability Act
S. 957, Drug Supply Chain Security Act
Issue related to prescription drug abuse, abuse deterrent drug formulations.
Lobbying Issues
S. 504 Fair And Immediate Release of Generic Drugs Act
S. 214 Preserve Access to Affordable Generics Act
generic drug label changes and preemption of federal law
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2013
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on July 18, 2013.
Original Filing: 300575023.xml
Lobbying Issues
S. 959, Pharmaceutical Compounding Quality and Accountability Act
S. 957, Drug Supply Chain Security Act
S.RES.97 : A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 504 Fair And Immediate Release of Generic Drugs Act
S. 214 Preserve Access to Affordable Generics Act
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2013
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on April 22, 2013.
Original Filing: 300559505.xml
Lobbying Issues
monitor Bennet-Burr Track and Trace/DDS legislation (no introduced bill)
Lobbying Issues
S. 214 Preserve Access to Affordable Generics Act; S. 504 Fair And Immediate Release of Generic Drugs Act
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2012
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on Jan. 14, 2013.
Original Filing: 300528113.xml
Lobbying Issues
Monitoring the impact of sequestration on FDA funding
H.R. 6190: Asthma Inhalers Relief Act of 2012
S. 1206 Medicare Drug Savings Act of 2011
Monitored draft pedigree legislation (Bennet-Burr)
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 27 Preserve Access to Generic Drugs
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2012
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on Oct. 18, 2012.
Original Filing: 300511851.xml
Lobbying Issues
H.R. 6433, the "FDA User Fee Corrections Act of 2012," which amends the Food and Drug Administration Safety and Innovation Act (Public Law 112-144) to make technical changes to both the generic drug user fee program and the medical device user fee program;
Monitoring the impact of sequestration on FDA funding
Monitoring supply chain safety
Agencies Lobbied
U.S. Senate
2nd Quarter, 2012
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on July 13, 2012.
Original Filing: 300483324.xml
Lobbying Issues
S. 27 Preserve Access to Generic Drugs; S. 1882 Fair and Immediate Release of Generic Drugs; S. 2295 Patient Safety and Generic Labeling Improvement Act of 2012
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
S. 3187 Food and Drug Administration Safety and Innovation Act
HR 5651 Food and Drug Administration Reform Act of 2012
drug shortage (HR 2245 and S 296)
Supply chain safety (S. 1584)
Agencies Lobbied
U.S. Senate
1st Quarter, 2012
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on April 10, 2012.
Original Filing: 300458716.xml
Lobbying Issues
FDA user fee bills (generic drug, prescription drug and biosimilar); drug shortage (S.296 and HR 2245); supply chain safety issues (S. 1584; Drug Safety and Accountability Act of 2011)
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 27 Preserve Access to Generic Drugs; S. 1882 Fair and Immediate Release of Generic Drugs
Type of Issue
Labor Issues/Antitrust/Workplace
4th Quarter, 2011
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on Jan. 18, 2012.
Original Filing: 300439783.xml
Lobbying Issues
FDA user fee agreements, S. 296 Preserving Access to Life-Saving Medications Act; and HR 2245 Preserving Access to Life-Saving Medications Act of 2011, S. 1882 Fair And Immediate Release of Generic Drugs Act, importation of prescription drugs (amendment HR 2112)
Agencies Lobbied
U.S. Senate
Lobbying Issues
HR 3342/S. 1356 Affordable Medicines Act of 2011; Medicaid Drug Rebates
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 27 Preserve Access to Generic Drugs
Type of Issue
Labor Issues/Antitrust/Workplace
3rd Quarter, 2011
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on Oct. 7, 2011.
Original Filing: 300411310.xml
Lobbying Issues
implementation of PPACA; generic drug user fee (no bill number); S. 296 Preserving Access to Life-Saving Medications Act of 2011;
Lobbying Issues
S. 23 America Invests Act
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 1356 Affordable Medicines Utilization Act of 2011; Medicaid drug rebates in the context of joint select committee negotiations.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 27 Preserve Access to Affordable Generics Act
Agencies Lobbied
U.S. Senate
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2011
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on July 19, 2011.
Original Filing: 300394415.xml
Lobbying Issues
implementation of Patient Protection and Affordable Care Act; Generic Drug User Fees (no bill yet); drug shortage (no bill yet).
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 23 America Invents Act; HR 1249 America Invents Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
S. 27 Preserve Access to Affordable Generics Act
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
S. 1356 Affordable Medicines Utilization Act of 2011; Medicaid drug rebates in context of debt limit legislation
Agencies Lobbied
U.S. Senate
1st Quarter, 2011
In Q1, Loper Consulting LLC lobbied for Teva Pharmaceuticals U.S.A. , earning $51,000. The report was filed on April 20, 2011.
Original Filing: 300377443.xml
Lobbying Issues
Implementation of the Patient Protection and Affordable Care Act
Medicaid generic utilization
Agencies Lobbied
Senate
4th Quarter, 2010
In Q4, Loper Consulting LLC lobbied for Teva Pharmaceuticals, U.S.A. , earning $51,000. The report was filed on Jan. 19, 2011.
Original Filing: 300343857.xml
Lobbying Issues
H.R. 3082 Continuing Appropriations and Surface Transportation
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 369 - A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drug in to the market, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Lobbying Issues
Health care implementation
P.L. 111-148 - The Patient Protection and Affordable Care Act
P.L. 111-152 - The Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2010
In Q3, Loper Consulting LLC lobbied for Teva Pharmaceuticals, U.S.A. , earning $51,000. The report was filed on Oct. 20, 2010.
Original Filing: 300326425.xml
Lobbying Issues
S. 515 - A bill to amend titl 35, United States Code, to provide Patent Reform
S. 610 - A bill to amend title 35, United States Code, to provide for Patent Reform
S. 3677 - FY 2011 Financial Services and General Government appropriations bill
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implentation of H.R. 3590 the Affordable Care Act;
Implementation of H.R. 4872 The Health Care and Education Reconcilaition Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1706 - To prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drugs in the market
S. 369 - To prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drugs in the market
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
2nd Quarter, 2010
In Q2, Loper Consulting LLC lobbied for Teva Pharmaceuticals, U.S.A. , earning $51,000. The report was filed on July 20, 2010.
Original Filing: 300301990.xml
Lobbying Issues
S. 515 A bill to amend title 35, United States Code, to provide Patent Reform
S. 610 - A bill to amend title 35, United States Code, to provide for Patent Reform
H.R. 1260 - to amend title 35, United States Code, to provide for Patent Reform
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 4851 - The Continuing Extensions Act of 2010
H.R. 4213 - Americqna Jobs and CLosing Loopholes Act of 2010
P.L. 111-148 - The Patient Protection and Affoirdable Care Act
P.L. 111-152 - The Reconcilaition Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1706 - To prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drug in to the market, and for other purposes.
S. 369 - A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drug in to the market, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
1st Quarter, 2010
In Q1, Loper Consulting, LLC lobbied for Teva Pharmaceuticals, U.S.A. , earning $50,000. The report was filed on April 19, 2010.
Original Filing: 300262572.xml
Lobbying Issues
S. 515 A bill to amend title 35, United States Code, to provide Patent Reform
S. 610 - A bill to amend title 35, United States Code, to provide for Patent Reform
H.R. 1260 - to amend title 35, United States Code, to provide for Patent Reform
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 1427 - to amend the Public Health Service Act to provide for the liscensing of biosimilar and biogeneric biological products, and for other purposes.
S. 726 - to amend the Public Health Service Act to provide for the liscensing of biosimilar and biogeneric biological products, and for other purposes. H.R. 3590 Patient Protection and Affordable Care Act
H.R. 4872 The Health Care and Education Reconcilation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 1706 - To prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drug in to the market, and for other purposes.
S. 369 - A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of generic drug in to the market, and for other purposes.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Labor Issues/Antitrust/Workplace
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...